Monday, May 2nd, 2022

08:30 // Registration and breakfast

09:15 // Welcome

09:30 // SESSION 1: Will molecular tests enable sustainable precision medicine? 

               Chair: Kristin Austlid Taskén, Oslo University Hospital (NO)

09:30 // How to use new biomarkers in treatment guidance of men with early prostate cancer?

              Stacy Loeb, New York University and the Manhattan Veterans Affairs Medical Center (US)

10:00 // Will biomarkers - other than PSA - be used to guide treatment of advanced prostate cancer?

              Nicolas Mottet,  University Hospital St. Etienne and University Jean Monnet  (FR)

10:30 // How cost-effective are biomarkers?

             Derya Tilki, Martini-Klinik Prostate Cancer Centre, Hamburg (DE)

11:00 // Break

11:30 // SESSION 2: Providing evidence for implementing molecular tests in clinical guidelines

              Chair: Rolf Skotheim, Oslo University Hospital (NO)

11:30 // Requirements for implementation of molecular tests into guidelines

              Himisha Beltran, Dana-Farber Cancer Institute and Harvard Medical School (US)

12:00 // Molecular stratification in clinical trials

              Johann de Bono, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust (UK)

12:30 // Design of biomarker-driven clinical trials (Sponsored by Tannlege Olaf Aase og Frues legat)

              Jason Connor, University of Central Florida's College of Medicine and ConfluenceStat LLC (US)

13:00 // Lunch

14:00 // How to bring molecular tests into the clinic in Scandinavia

              Henrik Grönberg, Karolinska Institutet and Capio S:t Göran Hospital (SE)

14:30 // Biomarker-driven precision medicine in Norway - where we are and where to go

    Hege Russnes, Oslo University Hospital (NO)

14:45 // Short talk - selected from abstracts

14:55 // Short talk - selected from abstracts

15:05 // Break

15:30 // Panel Discussion (in Norwegian)

              - How and when can molecular tests provide sustainable precision medicine in the clinic?

              Moderator Elisabeth Kirkeng Andersen (NO)

16:30 // Poster session

18:00 // Social activities and Dinner (including Poster Awards)

Tuesday, May 3rd, 2022

09:00 // SESSION 3: Precision medicine: impact of the tumour environment 

              Chair: Heidi Lyng, Oslo University Hospital (NO)

09:00 // Everything in balance? Metabolism reprograms cells

              Ian Mills, University of Oxford, Queen’s University of Belfast and University of Cambridge (UK) ​

09:30 // Hypoxia and subclonal evolution 

              Rob Bristow, Manchester Cancer Research Centre, CRUK Major research Centre, University of Manchester (UK)

10:00 // How can we move forward with immunotherapy in prostate cancer?  

              Johanna Olweus, Oslo University Hospital (NO)

10:15 // Break

10:45 // Discovery and testing of biomarkers and drugs in ex vivo and in vivo model systems

              Wytske van Weerden, Erasmus Medical Center (NL)

11:15 // Biomarker potential of tumor hypoxia

              Heidi Lyng, Oslo University Hospital (NO)

11:30 // Lunch 

12:30 // Drug efficacy in ex vivo model systems

              Olli Kallioniemi, Karolinska Institutet (SE)

13:00 // SESSION 4: Pitfalls and opportunities in biomarker discovery

              Alicia Llorente, Oslo University Hospital (NO)

13:00 // Tumor heterogeneity: a challenge to biomarker research

              Håvard Danielsen, Oslo University Hospital (NO)

13:15 // Lineage plasticity in prostate cancer

              Mark Rubin, University of Bern (CH)

13:45 // Extracellular vesicles - from lab to clinical implementation

              Johan Skog, Exosome Diagnostics (US) 

14:15 // Break

14:35 // Exploring precision oncology: From gene fusions to lncRNAs

              Arul Chinnaiyan, Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)

15:05 // Multifocal prostate cancer and implications for precision oncology

              Rolf Skotheim, Oslo University Hospital (NO)

15:15 // Short talk- selected from abstracts

15:25 // European network for biomarker validation

              Guido Jenster, Erasmus Medical Centre (NL)

15:55 // Closing remarks